Hyperbaric XXXX in the treatment of @entity2459 .

@entity1 @entity26 @entity1502 @entity393 @entity2459
Treatment of idiopathic @entity2459 ( @entity2459 ) is still a great problem for the physicians, due to the still unexplained etiopathogenesis of the disease. This retrospective study includes 115 @entity1 with idiopathic @entity2459 and compares two therapy regimens. Of the total number of @entity1 , 51 had been primarily treated by hyperbaric @entity26 (HBO) at 2.8 bar. The remaining 64 @entity1 had been treated by @entity1502 infusions in increasing and decreasing doses. Hearing thresholds were ascertained at the frequencies of 250, 500, 1,000, 2,000 and 4,000 Hz using pure-tone audiometry. The results after treatment showed a statistically significant improvement of hearing by 46.35 (SD +/-18.58) dB hearing level (HL) in the group of @entity1 treated with HBO, compared with an improvement of hearing by 21.48 dB HL (SD +/-13.5) in the group of @entity1 treated with @entity1502 infusions (p < 0.001). Furthermore, hearing recovered to physiological values in 24 of 51 (47.1%) HBO-treated @entity1 , compared to only 4 of 64 (6.2%) of the @entity1502 -treated @entity1 . Furthermore, after @entity1502 treatment only 8/64 (12.5%) @entity1 showed partial recovery, whereas after HBO therapy 21/51 (41.2%) @entity1 improved up to a mild persistent @entity393 . This indicates strong evidence that HBO therapy is more effective in the treatment of idiopathic @entity2459 than conventional rheological treatment. However, more prospective clinical trials should confirm the efficiency of HBO therapy and lead to its wider application.
